findmyKOL

Dawn Hershman, MD

Enriched profile

Witten Family Professor of Medicine, American Cancer Society Professor of Medicine and Epidemiology · Columbia University Irving Medical Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyMedical OncologyFocusCancer survivorship and care+4
Active KOLfindmyKOL type: EliteLatest publicationSee ScholarshipOnline presenceNone verifiedPayments2021–2025NIH funding2002–2026Why? →

Dawn Hershman is Witten Family Professor of Medicine, American Cancer Society Professor of Medicine and Epidemiology at Columbia University Irving Medical Center. OpenAlex indexes 1,278 publications with 42,795 citations (h-index 103); ClinicalTrials.gov lists 23 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.

Data verified 21 Oct 2026

Overview

Updated 23 Oct 2026

Dawn Hershman, M.D., is Witten Family Professor of Medicine, American Cancer Society Professor of Medicine and Epidemiology at Columbia University Irving Medical Center. The public record shows 1,278 publications with 42,795 citations (h-index 103), centered on Cancer survivorship and care, Breast Cancer Treatment Studies, Endometrial and Cervical Cancer Treatments. It also documents an investigator role on 23 registered clinical trials, industry payments reported by 7 companies, 14 NIH-funded awards (2002–2026).

  • Top research focus: Cancer survivorship and care
  • 23 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 7 companies

Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer21 trialsPain5 trialsOsteoporosis2 trialsArthralgia2 trialsColorectal Cancer2 trialsBreast Neoplasms, Male1 trialDepression (MDD)1 trialRectal Neoplasms1 trialFatigue1 trialSubstance Use Disorders1 trialColonic Neoplasms1 trialHypercalcemia1 trial

Research focus

OpenAlex concept fingerprint
Cancer survivorship and careBreast Cancer Treatment StudiesEndometrial and Cervical Cancer TreatmentsCancer Risks and FactorsGlobal Cancer Incidence and Screening

Drugs & molecules

across trials, industry payments and publications
Kisqaligeneric · RibociclibClinical trials—Industry payments3Publications—Piqraygeneric · AlpelisibClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Columbia UniversityClinical trials11Industry payments—SWOG Cancer Research NetworkClinical trials6Industry payments—Novartis Pharmaceuticals CorporationClinical trials—Industry payments3Dawn L. HershmanClinical trials2Industry payments—National Cancer Institute (NCI)Clinical trials2Industry payments—AstraZeneca Pharmaceuticals LPClinical trials—Industry payments1AstraZeneca UK LimitedClinical trials—Industry payments1Covis Pharma GmBHClinical trials—Industry payments1Gilead Sciences, Inc.Clinical trials—Industry payments1Herbert Irving Comprehensive Cancer CenterClinical trials1Industry payments—Leica Microsystems Inc.Clinical trials—Industry payments1NCIC Clinical Trials GroupClinical trials1Industry payments—TerSera Therapeutics LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,278publications

Distinct works indexed by OpenAlex, matched via ORCID; 65 in PubMed.

42,795citations

Total citations across indexed works.

103h-index

Hirsch index (OpenAlex). i10-index 501.

Clinical & industry

trials, payments and federal funding
23clinical trials

Investigator role on registered studies.

View trials ↓
7companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
14NIH grants · 2002–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 23 Oct 2026

Listed as an investigator on 23 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 23 Oct 2026

7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    87.8%
    Aromatase Inhibitor81.3%
    Anastrozole83%Letrozole9%Exemestane8%
    Part D<11 patients
    Estrogen Agonist/Antagonist6.5%
    Tamoxifen Citrate100%
    Part D<11 patients
  • Nervous system

    4.8%
    Phenothiazine4.8%
    Prochlorperazine Maleate100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    3.7%
    Serotonin-3 Receptor Antagonist3.7%
    Ondansetron Hcl100%
    Part D<11 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 23 Oct 2026

14 NIH research awards on record, funded 2002–2026 per NIH RePORTER. The latest:

All 84 award records: search, sort and filter.Explore →

Congress activity

Updated 23 Oct 2026

278 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Network

Updated 23 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Jason Dennis Wright405Alfred I. Neugut344Katherine D. Crew240Melissa Kate Accordino232Joseph M. Unger201June YiJuan Hou186Kevin M. Kalinsky180Ana Isabel Tergas178Heather Greenlee113Cande V. Ananth110Hanina H. Hibshoosh103Scott David Ramsey96Emerson A. Lim84William M. Burke83Yongmei Huang80Melissa Beauchemin78Meghna S. Trivedi77Alexander Melamed67Caryn M. St. Clair67Gary K. Schwartz64Prabhjot Singh Mundi62Jeffrey N. Bruce62Todd Louis Rosenblat61Andrea Califano61Andrew B. Lassman60Frances Brogan58Mary Roberta Welch57Mariano J. Alvarez57Teri Nguyen Kreisl57Grace Clarke Hillyer57Catherine A. Shu57Brian S. Henick57FABIO MASSAITI IWAMOTO57Gulam Abbas Manji56Filemon S. Dela Cruz55Guy M. McKhann55Michael D. Kluger55Ravi Pokala Kiran55Charles Karan54Suzanne Mistretta54

Background & recognition

Updated 23 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.